About SURGINEX
SURGINEX is a company based in Seoul (South Korea) founded in 2020. SURGINEX has raised $6.31 million across 1 funding round from investors including Laguna Investment, Kiwoom Investment and Partners Investment. SURGINEX offers products and services including Customized Exosome, Gene Experiments, Molecular Biological Service, Histopathological Service, and Animal Experiments Service. SURGINEX operates in a competitive market with competitors including Owkin, Formation Bio, AbSci, BigHat and Predictive Oncology, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Surginex Co., Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.31 M (USD)
in 1 rounds
-
Latest Funding Round
$6.31 M (USD), Series A
Mar 30, 2024
-
Investors
Laguna Investment
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SURGINEX
SURGINEX offers a comprehensive portfolio of products and services, including Customized Exosome, Gene Experiments, Molecular Biological Service, Histopathological Service, and Animal Experiments Service.
Tailored exosomes for targeted drug delivery applications.
Custom CRISPR/Cas9 designs for genetic research and therapy.
RNA and protein analysis for biological and pharmaceutical studies.
Tissue slide preparation and analysis for pathology research.
Provision of models for disease-specific animal testing.
Funding Insights of SURGINEX
SURGINEX has successfully raised a total of $6.31M through 1 strategic funding round. The most recent funding activity was a Series A round of $6.31 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SURGINEX
SURGINEX has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Laguna Investment, Kiwoom Investment and Partners Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Laguna Investment is engaged in venture capital funding for startups.
|
Locked | Locked | Locked | |
|
Investment services are offered by Kiwoom Investment in South Korea.
|
Locked | Locked | Locked | |
|
PE firm investing in South Korea and the US
|
Locked | Locked | Locked |
Investor details for SURGINEX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SURGINEX
Investment portfolio details for SURGINEX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SURGINEX
Detailed financials for SURGINEX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Surginex Comparisons
Peer comparison for SURGINEX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SURGINEX
SURGINEX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Owkin, Formation Bio, AbSci, BigHat and Predictive Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An agentic AI platform is developed for biomedical research insights.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
AI-based technology is used for recombinant protein production in therapeutics.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| Locked | Locked | Locked |
AI-based platform for cancer diagnostics and precision medicine is utilized.
|
|
| Locked | Locked | Locked |
AI platform used for extracting antibody data from scientific papers.
|
Detailed competitors of SURGINEX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Surginex
Complete news archive for SURGINEX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SURGINEX
SURGINEX was founded in 2020 and raised its 1st funding round 4 years after it was founded.
SURGINEX is headquartered in Seoul, South Korea.
Sejun Kim is the current CEO of SURGINEX.
SURGINEX is a funded company, having raised a total of $6.31M across 1 funding round to date.
SURGINEX was established in 2020 in Seoul, South Korea, within the biotechnology sector. An AI-driven platform for drug discovery is offered, alongside a bio-platform supporting drug development, molecular biology experiments, animal testing, and clinical trials. Next-generation lipid nanoparticles for drug delivery are developed, as well as a gallstone-dissolving platform, the SURGI healer system, and SURGI liver technology for liver regeneration using processed stem cell secretions.
SURGINEX's top competitors include Owkin, Formation Bio and XtalPi.
SURGINEX offers Customized Exosome, Gene Experiments, Molecular Biological Service, Histopathological Service, and Animal Experiments Service.
SURGINEX has 6 investors. Key investors include Laguna Investment, Kiwoom Investment, Partners Investment, Hana Ventures, and POSCO Capital.